Astellas Pharma Gmbh

Shigeki Kunikawa

Tomoyoshi Imaizumi

Takanori Koike

Susumu Yamaki

Itsuro Shimada

Kazuyuki Kuramoto

Michinori Akaiwa

Keisuke Arakawa

Ryo Sato

Satoshi Aoki

Hiroshi Yamada

Akira Tanaka

Tomoaki Abe

Kazushi Watanabe

Takahiro Nigawara

Shimpei Kawakami

Takanobu Araki

Yoshiki Satake

Masashi Shimazaki

Koichi Yonezawa

Satoshi Miyamoto

Hidenori Ohki

Akio Kamikawa

Naoyuki Masuda

Yutaka Nakajima

Hisao Hamaguchi

Masataka Morita

Takayuki Inoue

Toshio Yamanaka

Hiroaki Mizuno

Shinya Nagashima

Hiroshi Sasaki

Shohei Shirakami

Takuya Makino

Junya Ishida

Yohei Koganemaru

Hiroaki Ohtake

Koichiro Mukoyoshi

Kazuo Nakai

Ayako Toda

Fumie Takahashi

Yu Harayama

Yuka Koizumi

Yasuyuki Higashi

Takashi Ogiyama

Keiko Hatanaka

Shuichirou Kakimoto

Junichi Shishikura

Junko Yarimizu

Keisuke Tamaki

[Problem] Provided is a compound which is useful as an active ingredient of a pharmaceutical composition for treating lung cancer. [Means for Solution] The present inventors have studied a compound useful as an active ingredient of a pharmaceutical composition for treating lung cancer, and as a result, it was found that a quinazoline compound has an excellent G12C mutation KRAS inhibitory activity, and which can be used as a therapeutic agent for lung cancer, and thereby the present invention has been completed. The quinazoline compound of the present invention and a salt thereof may be used as the therapeutic agent for lung cancer.

Quinazoline compound

Compounds of formula (I) defined herein are useful as a dopamine D1 receptor positive allosteric modulators (D1 PAM) and can be used as an active ingredient of a pharmaceutical composition for preventing and/or treating cognitive impairment, schizophrenia negative symptom, CIAS, Parkinson's disease, Alzheimer's disease, Huntington's disease, depression, ADHD, drug dependency, or the like.

Imidazodiazepine compound

[Problem] Provided is a compound having a positive allosteric modulating activity (PAM activity) on an &#x3b1;7 nicotinic acetylcholine receptor (&#x3b1;7 nACh receptor). [Means for Solution] The present inventors have studied on a PAM activity on an &#x3b1;7 nACh receptor, and they have found that a tetrahydrooxepinopyridine compound has a PAM activity on an &#x3b1;7 nACh receptor, thereby completing the present invention. The tetrahydrooxepinopyridine compound of the present invention has a PAM activity on an &#x3b1;7 nACh receptor and can be expected as an agent for preventing or treating dementia, cognitive impairment, schizophrenia, Alzheimer's disease, CIAS, negative symptoms of schizophrenia, inflammatory diseases, or pain.

Tetrahydrooxepinopyridine compound

The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, a process for preparation thereof, a pharmaceutical composition comprising the same, and a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal.

Cyclic peptide compounds

The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia). 

Heterocyclic janus kinase 3 inhibitors

Growing community of inventors

Tokyo, Japan

Shigeki Kunikawa